Benefits and harms of atypical antipsychotics for agitation in adults with dementia

European Neuropsychopharmacology

Volumn 27, Issue 3, 2017, Pages 217-231

  Farlow, Martin R ^a   Shamliyan, Tatyana A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELSEVIER MASSON   (France)

Author keywords

Aripiprazole; Atypical antipsychotics; Evidence based medicine; Olanzapine; Quality of evidence; Quetiapine; Risperidone

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; ESCITALOPRAM; GALANTAMINE; ILOPERIDONE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGITATION; APATHY; BEHAVIOR DISORDER; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONSTIPATION; DATA BASE; DEMENTIA; DISEASE ASSOCIATION; DRUG SAFETY; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FRACTURE; GAIT DISORDER; HEART ARREST; HIP FRACTURE; HUMAN; META ANALYSIS (TOPIC); MORTALITY RATE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; COMPLICATION; PSYCHOLOGICAL RATING SCALE; RESTLESSNESS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DEMENTIA; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; TREATMENT OUTCOME;

EID: 85009729285     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2017.01.002     Document Type: Review

References (64)

1. Alva, G., Ellison, N., Hendrix, S., Pejovic, V., Otcheretko, V., Adding memantine to stable cholinesterase inhibitor therapy in patients with moderate to severe alzheimer׳s disease is associated with improvement in various neuropsychiatric symptoms: a pooled analysis. Neurology, 2015.
2. AstraZeneca Pharmaceuticals LP. Seroquel (quetiapine fumarate) package insert. Wilmington, DE. 2016;June (available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020639s064lbl.pdf) (accessed October 2016).
3. Azoulay, L., Yin, H., Renoux, C., Suissa, S., The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res. Treat. 129 (2011), 541–548.
4. Bago Rozankovic, P., Badzak, J., Impact of donepezil and memantine on behavioral and psychological symptoms in patients with Alzheimer׳s disease. Neuro-Degener. Dis., 2015, 744.
5. Ballard, C., Creese, B., Corbett, A., Aarsland, D., Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin. Drug Saf. 10 (2011), 35–43.
6. Balshem, H., Stevens, A., Ansari, M., Norris, S., Kansagara, D., Shamliyan, T., Chou, R., Chung, M., Moher, D., Dickersin, K., 2008. Finding grey literature evidence and assessing for outcome and analysis reporting biases when comparing medical interventions: AHRQ and the effective health care program, methods guide for effectiveness and comparative effectiveness reviews, Rockville (MD).
7. Barak, Y., Plopski, I., Tadger, S., Paleacu, D., Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer׳s disease: a randomized double-blind pilot study. Int. Psychogeriatr. 23 (2011), 1515–1519.
8. Brodaty, H., Ames, D., Snowdon, J., Woodward, M., Kirwan, J., Clarnette, R., Lee, E., Lyons, B., Grossman, F., A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J. Clin. Psychiatry 64 (2003), 134–143.
9. Brooks M., 2015. 100 Best-selling, most prescribed branded drugs through June. Medscape Medical News, WebMD, LLC Aug 13.
10. Brouwers, M.C., Kho, M.E., Browman, G.P., Burgers, J.S., Cluzeau, F., Feder, G., Fervers, B., Graham, I.D., Hanna, S.E., Makarski, J., Consortium, A.N.S., Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ: Can. Med. Assoc. J. = J. De. l׳Assoc. Medicale Can. 182 (2010), 1045–1052.
11. Brouwers, M.C., Kho, M.E., Browman, G.P., Burgers, J.S., Cluzeau, F., Feder, G., Fervers, B., Graham, I.D., Hanna, S.E., Makarski, J., Consortium, A.N.S., Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ: Can. Med. Assoc. J. = J. De. l׳Assoc. medicale Can. 182 (2010), E472–E478.
12. Bristol-Myers Squibb Company. Abilify (aripiprazole) tablets, discmelt orally-disintegrating tablets, oral solution, and intramuscular injection package insert. Princeton, NJ. 216; August (available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/21436s04021713s03121729s02321866s025lbl.pdf) (accessed October 2016).
13. Chatterjee, S., Chen, H., Johnson, M.L., Aparasu, R.R., Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study. Drugs Aging 29 (2012), 807–817.
14. Eli Lilly and Company. Zyprexa (olanzapine, all formulations) package insert. Indianapolis, IN. 2015; July (available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020592s064,021086s042,021253s049lbl.pdf) (accessed October 2016).
15. Culo, S., Mulsant, B.H., Rosen, J., Mazumdar, S., Blakesley, R.E., Houck, P.R., Pollock, B.G., Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis. Assoc. Disord. 24 (2010), 360–364.
16. De Deyn, P., Jeste, D.V., Swanink, R., Kostic, D., Breder, C., Aripiprazole for the treatment of psychosis in patients with Alzheimer׳s disease: a randomized, placebo-controlled study. J. Clin. Psychopharmacol. 25 (2005), 463–467.
17. De Deyn, P.P., Carrasco, M.M., Deberdt, W., Jeandel, C., Hay, D.P., Feldman, P.D., Young, C.A., Lehman, D.L., Breier, A., Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer׳s disease. Int. J. Geriatr. Psychiatry 19 (2004), 115–126.
18. De Deyn, P.P., Eriksson, H., Svensson, H., Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer׳s disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study. Int. J. Geriatr. Psychiatry 27 (2012), 296–304.
19. De Deyn, P.P., Rabheru, K., Rasmussen, A., Bocksberger, J.P., Dautzenberg, P.L.J., Eriksson, S., Lawlor, B.A., A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53 (1999), 946–955.
20. Deberdt, W.G., Dysken, M.W., Rappaport, S.A., Feldman, P.D., Young, C.A., Hay, D.P., Lehman, D.L., Dossenbach, M., Degenhardt, E.K., Breier, A., Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am. J. Geriatr. Psychiatry 13 (2005), 722–730.
21. Devanand, D.P., Mintzer, J., Schultz, S.K., Andrews, H.F., Sultzer, D.L., de la Pena, D., Gupta, S., Colon, S., Schimming, C., Pelton, G.H., Levin, B., Relapse risk after discontinuation of risperidone in Alzheimer׳s disease. N. Engl. J. Med 367 (2012), 1497–1507.
22. Freund-Levi, Y., Bloniecki, V., Auestad, B., Tysen Backstrom, A.C., Larksater, M., Aarsland, D., Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. Dement. Geriatr. Cogn. Disord. 38 (2014), 234–244.
23. Fu, R., Gartlehner, G., Grant, M., Shamliyan, T., Sedrakyan, A., Wilt, T.J., Griffith, L., Oremus, M., Raina, P., Ismaila, A., Santaguida, P., Lau, J., Trikalinos, T.A., Conducting quantitative synthesis when comparing medical interventions: ahrq and the Effective Health Care Program. J. Clin. Epidemiol. 64 (2011), 1187–1197.
24. Gallagher, D., Herrmann, N., Agitation and aggression in Alzheimer׳s disease: an update on pharmacological and psychosocial approaches to care. Neurodegener. Dis. Manag. 5 (2015), 77–83.
25. Gentile, S., Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacol. (Berl.) 212 (2010), 119–129.
26. Higgins, J., Green, S., Cochrane handbook for systematic reviews of interventions. Version 5.1.0, Cochrane book series. 2011, The Cochrane, Collaboration Available at: http://handbook.cochrane.org/v5.0.2/ (accessed January 2017).
27. Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., Savovic, J., Schulz, K.F., Weeks, L., Sterne, J.A., The Cochrane Collaboration׳s tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
28. Huybrechts, K.F., Gerhard, T., Crystal, S., Olfson, M., Avorn, J., Levin, R., Lucas, J.A., Schneeweiss, S., Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ, 344, 2012, e977.
29. Jalbert, J.J., Daiello, L.A., Eaton, C.B., Miller, S.C., Lapane, K.L., Antipsychotic use and the risk of diabetes in nursing home residents with dementia. Am. J Geriatr. Pharmacother. 9 (2011), 153–163.
30. Jalbert, J.J., Eaton, C.B., Miller, S.C., Lapane, K.L., Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J. Am. Med. Dir. Assoc. 11 (2010), 120–127.
31. Janssen Pharmaceuticals I. Risperdal (risperidone tablets, oral solution, and orally disintegrating tablets) package insert. Titusville, NJ. 2016; March (available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020272s077,020588s065,021346s055,021444s051lbl.pdf) (accessed October 2016).
32. Kales, H.C., Kim, H.M., Zivin, K., Valenstein, M., Seyfried, L.S., Chiang, C., Cunningham, F., Schneider, L.S., Blow, F.C., Risk of mortality among individual antipsychotics in patients with dementia. Am. J. Psychiatry 169 (2012), 71–79.
33. Katz, I.R., Jeste, D.V., Mintzer, J.E., Clyde, C., Napolitano, J., Brecher, M., Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J. Clin. Psychiatry 60 (1999), 107–115.
34. Kurlan, R., Cummings, J., Raman, R., Thal, L., Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68 (2007), 1356–1363.
35. Langballe, E.M., Engdahl, B., Nordeng, H., Ballard, C., Aarsland, D., Selbaek, G., Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am. J. Geriatr. Psychiatry 22 (2014), 321–331.
36. Levinson, D., Medicare Atypical Antipsychotic Drug Claims for Elderly Nursing Home Residents. 2011, Department of Health and Human Services (OFFICE OF INSPECTOR GENERAL OEI-07-08-00150).
37. Lin, S.T., Chen, C.C., Tsang, H.Y., Lee, C.S., Yang, P., Cheng, K.D., Li, D.J., Wang, C.J., Hsieh, Y.C., Yang, W.C., Association between antipsychotic use and risk of acute myocardial infarction: a nationwide case-crossover study. Circulation 130 (2014), 235–243.
38. Liperoti, R., Onder, G., Landi, F., Lapane, K.L., Mor, V., Bernabei, R., Gambassi, G., All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J. Clin. Psychiatry 70 (2009), 1340–1347.
39. Maglione, M., Maher, A.R., Hu, J., Wang, Z., Shanman, R., Shekelle, P.G., Roth, B., Hilton, L., Suttorp, M.J., Ewing, B.A., Motala, A., Perry, T., 2011. Off-label use of atypical antipsychotics: an update, Rockville MD.
40. Maust, D.T., Kim, H.M., Seyfried, L.S., Chiang, C., Kavanagh, J., Schneider, L.S., Kales, H.C., Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 72 (2015), 438–445.
41. Mintzer, J., Greenspan, A., Caers, I., Van Hove, I., Kushner, S., Weiner, M., Gharabawi, G., Schneider, L.S., Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am. J. Geriatric Psychiatry 14 (2006), 280–291.
42. Mowla, A., Pani, A., Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J. Clin. Psychopharmacol. 30 (2010), 40–43.
43. National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management. NG56. 2016; available at: https://www.nice.org.uk/guidance/NG56/chapter/recommendations#delivering-an-approach-to-care-that-takes-account-of-multimorbidity (accessed October 2016).
44. Otsuka Pharmaceutical DC, Inc, Otsuka America P. Aripiprazole in the Treatment of Patients with Psychosis Associated with Dementia of Alzheimer's type; 2010. https://clinicaltrialsgov/ct2/show/NCT01438060 (accessed January 2017).
45. Paleacu, D., Barak, Y., Mirecky, I., Mazeh, D., Quetiapine treatmdnt for behavioural and psychological symptoms of dementia in alzheimer׳s disease patients: a 6-week, double-blind, placebo-controlled study. Int. J. Geriatr. Psychiatry 23 (2008), 393–400.
46. Reus, V.I., Fochtmann, L.J., Eyler, A.E., Hilty, D.M., Horvitz-Lennon, M., Jibson, M.D., Lopez, O.L., Mahoney, J., Pasic, J., Tan, Z.S., Wills, C.D., Rhoads, R., Yager, J., The American psychiatric association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am. J. Psychiatry 173 (2016), 543–546.
47. Schneider, L.S., Tariot, P.N., Dagerman, K.S., Davis, S.M., Hsiao, J.K., Ismail, M.S., Lebowitz, B.D., Lyketsos, C.G., Ryan, J.M., Stroup, T.S., Sultzer, D.L., Weintraub, D., Lieberman, J.A., Effectiveness of atypical antipsychotic drugs in patients with Alzheimer׳s disease. N. Engl. J. Med. 355 (2006), 1525–1538.
48. Schünemann H, B.J., Guyatt G., Oxman A., 2013. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. 〈http://gdt.guidelinedevelopment.org/app/handbook/handbook.html〉 Acessed on September 20 2016.
49. Seitz, D.P., Adunuri, N., Gill, S.S., Gruneir, A., Herrmann, N., Rochon, P., Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst. Rev, 2011.
50. Shea, B.J., Hamel, C., Wells, G.A., Bouter, L.M., Kristjansson, E., Grimshaw, J., Henry, D.A., Boers, M., AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J. Clin. Epidemiol. 62 (2009), 1013–1020.
51. Sink, K.M., Holden, K.F., Yaffe, K., Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293 (2005), 596–608.
52. Slutsky, J., Atkins, D., Chang, S., Sharp, B.A., AHRQ series paper 1: comparing medical interventions: ahrq and the effective health-care program. J. Clin. Epidemiol. 63 (2010), 481–483.
53. Street, J.S., Clark, W.S., Gannon, K.S., Cummings, J.L., Bymaster, F.P., Tamura, R.N., Mitan, S.J., Kadam, D.L., Sanger, T.M., Feldman, P.D., Tollefson, G.D., Breier, A., Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch. General. Psychiatry 57 (2000), 968–976.
54. Streim, J.E., Porsteinsson, A.P., Breder, C.D., Swanink, R., Marcus, R., McQuade, R., Carson, W.H., A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am. J Geriatr. Psychiatry 16 (2008), 537–550.
55. Sultzer, D.L., Davis, S.M., Tariot, P.N., Dagerman, K.S., Lebowitz, B.D., Lyketsos, C.G., Rosenheck, R.A., Hsiao, J.K., Lieberman, J.A., Schneider, L.S., Clinical symptom responses to atypical antipsychotic medications in Alzheimer׳s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am. J. Psychiatry 165 (2008), 844–854.
56. Tan, L., Tan, L., Wang, H.F., Wang, J., Tan, C.C., Tan, M.S., Meng, X.F., Wang, C., Yu, J.T., Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimers Res. Ther., 7, 2015, 20.
57. Tariot, P.N., Schneider, L., Katz, I.R., Mintzer, J.E., Street, J., Copenhaver, M., Williams-Hughes, C., Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am. J. Geriatr. Psychiatry 14 (2006), 767–776.
58. Tariot, P.S., Katz, L., Mintzer, I., Street, J., 2002. Quetiapine in nursing home residents with Alzheimer's dementia and psychosis. Annual Meeting of the American Association of Geriatric Psychiatry; February 24–27; Orlando, FL.
59. Thompson Coon, J., Abbott, R., Rogers, M., Whear, R., Pearson, S., Lang, I., Cartmell, N., Stein, K., Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review. J. Am. Med. Dir. Assoc. 15 (2014), 706–718.
60. Vance, J., AMDA-choosing wisely. J Am. Med Dir. Assoc. 14 (2013), 639–641.
61. Vasilyeva, I., Biscontri, R.G., Enns, M.W., Metge, C.J., Alessi-Severini, S., Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study. PLoS One, 8, 2013, e64217.
62. Viswanathan, M., Berkman, N.D., Dryden, D.M., Hartling, L., 2013. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI Item Bank. AHRQ Methods for Effective Health Care Contract No. 290-2007-10056-I.
63. Wang, M.T., Li, M.F., Chu, C.L., Yeh, C.B., Tsai, C.L., Liou, J.T., Evaluation of stroke risk associated with the use of typical or atypical antipsychotics among patients with cardiovascular diseases. J. Med. Sci. (Taiwan) 35 (2015), 11–18.
64. Zhong, K.X., Tariot, P.N., Mintzer, J., Minkwitz, M.C., Devine, N.A., Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr. Alzheimer Res. 4 (2007), 81–93.